Moreover, Chen et al. reported that the level of pre-treatment circulating exosomal PD-L1 was related to the response rate of anti-PD-L1 monoclonal antibodies (mAbs), suggesting the importance of exosomal PD-L1 for anti-PD-1/PD-L1 tumor therapy [5]. The gene discussed is CD274; the disease is neoplasm.